AbbVie lowers 2026 adjusted EPS guidance to $13.76 to $13.96 including Q3 expense

AbbVie said results for the quarter ended September 30, 2026 have not been finalized and remain subject to its financial statement closing procedures. It said there can be no assurance that its final results will not differ from these preliminary estimates.

AbbVie said its full-year 2026 adjusted diluted EPS guidance, including the third-quarter expense, is $13.76 to $13.96. Its previous range, announced July 31, 2026, excluded acquired IPR&D and milestones expense incurred beyond the second quarter, and was $13.87 to $14.07.

AbbVie said its third-quarter 2026 adjusted diluted EPS guidance, including the expense, is $3.73 to $3.77, compared with a previously announced $3.84 to $3.88 that excluded it.

AbbVie said it does not forecast acquired IPR&D and milestones expense because the occurrence and timing of collaborations, licensing agreements and other asset acquisitions are uncertain. It said such expense may be incurred when those agreements are executed. It said its 2026 guidance excludes any such expense incurred beyond the third quarter, as both cannot be reliably forecasted.